Johanna Richter

Johanna Richter

Auto-generated profile, based on publicly available information

Johanna Richter

Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2019 in Clinical Infectious Diseases
Verified
Journal Article
Open access
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
SBStephan Brouwer
Stephan Brouwer
BFBrian M Forde
Brian M Forde
KWKate A Worthing
Kate A Worthing
LMLiam McIntyre
Liam McIntyre
MDMark Davies
Mark Davies
Sentinel hospital surveillance was instituted in Australia to detect the presence of pandemic group A Streptococcus strains causing scarlet fever. Genomic and phylogenetic analyses indicated the presence of an Australian GAS emm12 scarlet fever isolate related to United Kingdom outbreak strains. National surveillance to monitor this pandemic is recommended.

30 August 2021 in Immunology & Cell Biology
Verified
Journal Article
Closed access
PDF file
JRJohanna Richter
Johanna Richter
MMMercedes M Monteleone
Mercedes M Monteleone
ACAmanda J Cork
Amanda J Cork
TBTimothy C. Barnett
Timothy C. Barnett
VNVictor Nizet
Victor Nizet
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker

21 June 2021 in Cellular Microbiology
Verified
Journal Article
Open access
PDF file
JRJohanna Richter
Johanna Richter
SBStephan Brouwer
Stephan Brouwer
KSKate Schroder
Kate Schroder
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
Group A Streptococcus (GAS) is a Gram-positive bacterial pathogen that causes significant morbidity and mortality worldwide. Recent clinical evidence suggests that the inflammatory marker interleukin-1β (IL-1β) plays an important role in GAS disease progression, and presents a potential target for therapeutic intervention. Interaction with GAS activates the host inflammasome pathway to stimulate production and secretion of IL-1β, but GAS can also stimulate IL-1β production in an inflammasome-independent manner. This review highlights progress that has been made in understanding the importance of host cell inflammasomes and IL-1 signalling in GAS disease, and explores challenges and unsolved problems in this host-pathogen interaction. Take Away Inflammasome signalling during GAS infection is an emerging field of research. GAS modulates the NLRP3 inflammasome pathway through multiple mechanisms. SpeB contributes to IL-1β production independently of the inflammasome pathway. IL-1β signalling can be host-protective, but also drive severe GAS disease.

1 April 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ELElizabeth A. Lemm
Elizabeth A. Lemm
BVBeatriz Valle-Argos
Beatriz Valle-Argos
LSLindsay D. Smith
Lindsay D. Smith
JRJohanna Richter
Johanna Richter
YGYohannes Gebreselassie
Yohannes Gebreselassie
GPGraham Packham
Graham Packham
Purpose: PI3K signaling is a common feature of B-cell neoplasms, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), and PI3K inhibitors have been introduced into the clinic. However, there remains a clear need to develop new strategies to target PI3K signaling. PI3K activity is countered by Src homology domain 2-containing inositol-5′-phosphatase 1 (SHIP1) and, here, we have characterized the activity of a novel SHIP1 activator, AQX-435, in preclinical models of B-cell malignancies.Experimental Design: In vitro activity of AQX-435 was evaluated using primary CLL cells and DLBCL-derived cell lines. In vivo activity of AQX-435, alone or in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, was assessed using DLBCL cell line and patient-derived xenograft models.Results: Pharmacologic activation of SHIP1 using AQX-435 was sufficient to inhibit anti–IgM-induced PI3K-mediated signaling, including induction of AKT phosphorylation and MYC expression, without effects on upstream SYK phosphorylation. AQX-435 also cooperated with the BTK inhibitor ibrutinib to enhance inhibition of anti–IgM-induced AKT phosphorylation. AQX-435 induced caspase-dependent apoptosis of CLL cells preferentially as compared with normal B cells, and overcame in vitro survival-promoting effects of microenvironmental stimuli. Finally, AQX-435 reduced AKT phosphorylation and growth of DLBCL in vivo and cooperated with ibrutinib for tumor growth inhibition.Conclusions: Our results using AQX-435 demonstrate that SHIP1 activation may be an effective novel therapeutic strategy for treatment of B-cell neoplasms, alone or in combination with ibrutinib.

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NHNichaela Harbison-Price
Nichaela Harbison-Price
ISIsmail Sebina
Ismail Sebina
RBRhiannon A. Bolton
Rhiannon A. Bolton
MFMeredith Finn
Meredith Finn
ACAmanda J. Cork
Amanda J. Cork
Mark Joseph WalkerMark Joseph Walker
Mark Joseph Walker
A commercial vaccine to address the high global burden of Group A Streptococcus (GAS) disease is an urgent and unmet medical need. Messenger RNA (mRNA) lipid-nanoparticle (LNP) vaccines represent a largely untapped platform for targeting bacterial pathogens. Here, we evaluate the immunogenicity and preclinical efficacy of a multicomponent mRNA-LNP vaccine formulation based on the GAS vaccine, Combo#5. Combo#5 mRNA-LNP antigens confer protection from infection in mouse intraperitoneal and subcutaneous challenge models. Combo#5 mRNA-LNP vaccination generates significantly increased frequencies and numbers of effector type CD4+ and CD8 + T cells in the spleen, enhances T follicular helper cells, germinal center B cells and memory B cells in the spleen and draining lymph nodes, and boosts the production of antigen-specific antibodies. These findings demonstrate the potential of the mRNA-LNP platform for the development of vaccines against bacterial pathogens.

5 February 2025 in mBio
Verified
Journal Article
Open access
JRJohanna Richter
Johanna Richter
ACAmanda J. Cork
Amanda J. Cork
YOYvette Ong
Yvette Ong
NKNadia Keller
Nadia Keller
AHAndrew J. Hayes
Andrew J. Hayes
SBStephan Brouwer
Stephan Brouwer
Group A Streptococcus (GAS) is a human-adapted pathogen responsible for a variety of diseases. The GAS M1 UK lineage has contributed significantly to the recently reported increases in scarlet fever and invasive infections. However, the basis for its evolutionary success is not yet fully understood. During the transition to systemic disease, the M1 serotype is known to give rise to spontaneous mutations in the control of virulence two-component regulatory system (CovRS) that confer a fitness advantage during invasive infections. Mutations that inactivate CovS function result in the de-repression of key GAS virulence factors such as streptolysin O (SLO), a pore-forming toxin and major trigger of inflammasome/interleukin-1β-dependent inflammation. Conversely, expression of the streptococcal cysteine protease SpeB, which is required during initial stages of colonization and onset of invasive disease, is typically lost in such mutants. In this study, we identified and characterized a novel covS single nucleotide polymorphism detected in three separate invasive M1 UK isolates. The resulting CovS Ala318Val mutation caused a significant upregulation of SLO resulting in increased inflammasome activation in human THP-1 macrophages, indicating an enhanced inflammatory potential. Surprisingly, SpeB production was unaffected. Site-directed mutagenesis was performed to assess the impact of this mutation on virulence and global gene expression. We found that the CovS Ala318Val mutation led to subtle, virulence-specific changes of the CovRS regulon compared to previously characterized covS mutations, highlighting an unappreciated level of complexity in CovRS-dependent gene regulation. Continued longitudinal surveillance is warranted to determine whether this novel covS mutation will expand in the M1 UK lineage. IMPORTANCE: The M1 UK lineage of GAS has contributed to a recent global upsurge in scarlet fever and invasive infections. Understanding how GAS can become more virulent is critical for infection control and identifying new treatment approaches. The two-component CovRS system, comprising the sensor kinase CovS and transcription factor CovR, is a central regulator of GAS virulence genes. In the M1 serotype, covRS mutations are associated with an invasive phenotype. Such mutations have not been fully characterized in the M1 UK lineage. This study identified a novel covS mutation in invasive Australian M1 UK isolates that resulted in a more nuanced virulence gene regulation compared to previously characterized covS mutations. A representative isolate displayed upregulated SLO production and triggered amplified interleukin-1β secretion in infected human macrophages, indicating an enhanced inflammatory potential. These findings underscore the need for comprehensive analyses of covRS mutants to fully elucidate their contribution to M1 UK virulence and persistence.